RISPERDAL CONSTA: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Janssen Pharms	RISPERDAL CONSTA	risperidone	POWDER;INTRAMUSCULAR	021346	NDA	Janssen Pharmaceuticals, Inc.	50458-306-11	1 KIT in 1 BOX (50458-306-11) * 2 mL in 1 SYRINGE (50458-306-01) * 2 mL in 1 VIAL	2003-10-29
Janssen Pharms	RISPERDAL CONSTA	risperidone	POWDER;INTRAMUSCULAR	021346	NDA	Janssen Pharmaceuticals, Inc.	50458-307-11	1 KIT in 1 BOX (50458-307-11) * 2 mL in 1 VIAL * 2 mL in 1 SYRINGE (50458-307-01)	2003-10-29
Janssen Pharms	RISPERDAL CONSTA	risperidone	POWDER;INTRAMUSCULAR	021346	NDA	Janssen Pharmaceuticals, Inc.	50458-308-11	1 KIT in 1 BOX (50458-308-11) * 2 mL in 1 VIAL * 2 mL in 1 SYRINGE (50458-308-01)	2003-10-29
Janssen Pharms	RISPERDAL CONSTA	risperidone	POWDER;INTRAMUSCULAR	021346	NDA	Janssen Pharmaceuticals, Inc.	50458-309-11	1 KIT in 1 BOX (50458-309-11) * 2 mL in 1 VIAL * 2 mL in 1 SYRINGE (50458-309-01)	2003-10-29
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This analysis identifies key suppliers involved in the manufacturing and distribution of RISPERDAL CONSTA, a long-acting injectable antipsychotic. The proprietary formulation and controlled manufacturing processes necessitate a specialized and reliable supply chain.

What is RISPERDAL CONSTA?

RISPERDAL CONSTA (risperidone) is an atypical antipsychotic medication administered as a long-acting intramuscular injection. It is indicated for the treatment of schizophrenia and schizoaffective disorder. The drug's active pharmaceutical ingredient (API), risperidone, is formulated within a biodegradable polymer microsphere system, providing sustained release over a two-week period. This sustained-release mechanism requires precise manufacturing and specialized excipients, influencing the nature of its supply chain. The drug was originally developed by Janssen Pharmaceutica, a subsidiary of Johnson & Johnson.

Key Components of RISPERDAL CONSTA Manufacturing

The production of RISPERDAL CONSTA involves several critical components:

Active Pharmaceutical Ingredient (API): Risperidone. The synthesis and purification of risperidone must meet stringent pharmaceutical standards.
Biodegradable Polymer: Poly(lactic-co-glycolic acid) (PLGA) is commonly used to encapsulate the risperidone and control its release rate. The specific molecular weight, copolymer ratio (lactic acid to glycolic acid), and end-capping of the PLGA are crucial for formulation performance.
Other Excipients: Buffers, stabilizers, and suspending agents are required to ensure product stability, injectability, and consistent drug release.
Sterile Manufacturing: The entire process, from API to final product, must occur under sterile conditions to prevent microbial contamination.
Packaging: Specialized vials and reconstitution kits are necessary for the safe and effective delivery of the drug.

Identification of RISPERDAL CONSTA Suppliers

Identifying specific contract manufacturers and raw material suppliers for a proprietary drug like RISPERDAL CONSTA is challenging due to confidential business agreements and trade secrets. However, based on industry practices, patent literature, and the regulatory landscape, the following categories of suppliers are essential:

1. Active Pharmaceutical Ingredient (API) Manufacturers

The primary API is risperidone. Companies specializing in complex organic synthesis and cGMP (current Good Manufacturing Practice) compliant API production are involved. Given Johnson & Johnson's (J&J) history with the drug, internal manufacturing or a long-term contract with a highly specialized CDMO (Contract Development and Manufacturing Organization) is likely.

Potential API Suppliers/Manufacturers:
- Johnson & Johnson / Janssen Pharmaceutical Companies: Large pharmaceutical companies often maintain in-house API manufacturing capabilities for their key products, especially during the initial patent-protected phase. This allows for direct control over quality and supply security.
- Specialized CDMOs with API Synthesis Expertise: Companies such as Catalent, Lonza, or Siegfried, which have extensive experience in producing complex APIs under cGMP, could be involved as contract manufacturers. Their capabilities would include multi-step organic synthesis, purification, and analytical testing.
- Asian API Manufacturers (with high regulatory compliance): While less likely for a proprietary J&J drug during its peak patent life, generic API manufacturers in India or China with established regulatory track records (e.g., US FDA, EMA approved sites) would become more relevant if J&J licensed out manufacturing or in anticipation of generic competition.

2. Polymer Suppliers for Microsphere Formulation

The biodegradable polymer, typically PLGA, is a critical and specialized raw material. The precise specifications of the PLGA are proprietary and directly impact the drug's release profile.

Key PLGA Suppliers:
- Evonik Industries: A major global supplier of specialty chemicals, including a broad range of PLGA polymers for drug delivery systems. Evonik's product lines like RESOMER® are well-established in the controlled-release pharmaceutical market.
- Boehringer Ingelheim (now part of Intellia Therapeutics for certain biotech aspects, but with historical chemical divisions): While Boehringer Ingelheim is primarily a pharmaceutical company, its chemical divisions have historically been involved in polymer science for drug delivery. Specific entities within or spun off from such large chemical/pharmaceutical conglomerates are potential suppliers.
- Specialty Polymer Manufacturers: Other niche manufacturers focusing on biodegradable polymers for biomedical applications, often with extensive R&D capabilities to customize polymer properties.

3. Fill-Finish and Sterile Manufacturing CDMOs

The formulation of the risperidone API into PLGA microspheres, followed by sterile filling into vials, is a highly specialized and capital-intensive process. This often involves dedicated manufacturing facilities with advanced aseptic processing capabilities.

Potential Fill-Finish CDMOs:
- Catalent: A leading global CDMO with extensive experience in sterile manufacturing, complex formulations, and drug-device combination products. They possess advanced capabilities for parenteral drug manufacturing.
- Lonza: Another major player in pharmaceutical contract manufacturing, Lonza offers comprehensive services including sterile drug product manufacturing, biologics, and specialized drug delivery technologies.
- Thermo Fisher Scientific (Patheon): Thermo Fisher's Patheon brand is a significant CDMO providing sterile manufacturing and formulation services for complex injectable drugs.
- Recipharm: A European-based CDMO that offers sterile manufacturing and development services for a wide range of dosage forms, including injectables.

4. Excipient and Raw Material Suppliers

Beyond the API and polymer, other excipients are needed for formulation, suspension, and stability.

Suppliers of Pharmaceutical Excipients: Companies that supply high-purity grades of ingredients like polysorbates, buffers (e.g., sodium phosphate, citrate), and suspending agents. Major suppliers include:
- BASF: A global chemical company with a significant pharmaceutical ingredients division.
- Ashland: Provides a range of excipients for pharmaceutical formulations.
- Croda International: Offers specialty excipients for pharmaceutical applications.

5. Packaging Component Suppliers

The final packaging requires sterile vials, stoppers, and syringes for reconstitution and administration.

Key Packaging Suppliers:
- Schott AG: A leading manufacturer of pharmaceutical glass tubing and containers, including vials and ampoules.
- Gerresheimer AG: Another major global supplier of pharmaceutical packaging products, including glass and plastic packaging.
- Datwyler: Provides high-quality sealing solutions, including stoppers for vials, for the pharmaceutical industry.
- Becton, Dickinson and Company (BD): A significant supplier of medical devices, including syringes and needles used for administering injectable drugs.

Regulatory Considerations and Supply Chain Oversight

The supply chain for RISPERDAL CONSTA is heavily regulated by health authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Key aspects include:

cGMP Compliance: All manufacturing sites for APIs, drug products, and critical packaging components must adhere to cGMP standards. This involves rigorous quality control, validation of processes, and robust quality management systems.
Drug Master Files (DMFs) / Active Substance Master Files (ASMFs): API manufacturers maintain these confidential documents detailing the chemistry, manufacturing, and controls of the API. These are submitted to regulatory authorities to support drug applications.
Supplier Qualification Programs: Pharmaceutical companies like J&J have extensive supplier qualification programs to ensure that all vendors meet strict quality, reliability, and compliance standards. This includes regular audits of manufacturing facilities and quality systems.
Supply Chain Security and Traceability: Measures to prevent counterfeiting and ensure product integrity throughout the supply chain are paramount. This can involve serialization and track-and-trace technologies.
Change Control: Any changes in suppliers, manufacturing processes, or materials require rigorous evaluation and regulatory notification or approval to ensure no adverse impact on product quality or efficacy.

Patent Landscape and Supplier Impact

The patent status of RISPERDAL CONSTA and its manufacturing processes directly influences the supplier landscape. During the patent-protected period, J&J would have maintained tight control over its manufacturing and supplied base. As patents expire, generic manufacturers become eligible to produce and market their own versions of risperidone long-acting injectables. This shift typically leads to:

Increased Competition for API Suppliers: Generic manufacturers will seek cost-effective sources of risperidone API from qualified suppliers.
Broader CDMO Engagement: Generic companies may engage a wider range of CDMOs for fill-finish operations, potentially seeking more competitive pricing.
Innovation in Formulation: New patents may emerge related to improved formulations, delivery devices, or manufacturing processes, potentially involving new polymer suppliers or CDMOs with specialized technologies.

Conclusion

The supply chain for RISPERDAL CONSTA is characterized by its reliance on specialized materials, precise manufacturing processes, and stringent regulatory oversight. Key suppliers include API manufacturers with expertise in complex synthesis, polymer producers specializing in biodegradable materials like PLGA, and CDMOs equipped for sterile fill-finish operations. Robust quality management and regulatory compliance are foundational to ensuring the consistent availability and safety of this important long-acting injectable medication.

Key Takeaways

RISPERDAL CONSTA's complex formulation requires specialized suppliers for its API (risperidone), biodegradable polymer (PLGA), and sterile manufacturing.
Key players in the supply chain include API synthesis specialists, polymer manufacturers like Evonik, and sterile fill-finish CDMOs such as Catalent, Lonza, and Thermo Fisher Scientific.
Strict adherence to cGMP, robust supplier qualification, and regulatory compliance are critical throughout the supply chain.
Patent expiry significantly alters the supplier landscape, opening opportunities for generic API manufacturers and a broader range of CDMOs.

Frequently Asked Questions

Who is the primary manufacturer of the RISPERDAL CONSTA active pharmaceutical ingredient (API)? The primary manufacturer of the risperidone API is likely Johnson & Johnson's Janssen Pharmaceutical Companies or a closely contracted, highly specialized CDMO, particularly during the drug's patent-protected period.
What type of polymer is used in RISPERDAL CONSTA, and who are the key suppliers? RISPERDAL CONSTA utilizes a biodegradable polymer, commonly poly(lactic-co-glycolic acid) (PLGA), for its controlled-release microsphere formulation. Key global suppliers of pharmaceutical-grade PLGA include Evonik Industries.
What are the main categories of contract manufacturing organizations (CDMOs) involved in producing RISPERDAL CONSTA? CDMOs involved would primarily focus on sterile fill-finish operations for injectable products and potentially API synthesis if not handled in-house by the innovator company. Leading sterile manufacturers include Catalent, Lonza, and Thermo Fisher Scientific (Patheon).
How does the patent status of RISPERDAL CONSTA affect its supply chain composition? During patent protection, the innovator company maintains tight control over suppliers. Post-patent expiry, the market opens for generic versions, leading to increased competition for API sources and a wider engagement of CDMOs, often with a focus on cost efficiency.
What regulatory requirements are most critical for suppliers in the RISPERDAL CONSTA supply chain? Suppliers must adhere to current Good Manufacturing Practices (cGMP), maintain robust quality management systems, and be subject to rigorous supplier qualification audits by the pharmaceutical company. Regulatory filings such as Drug Master Files (DMFs) for APIs are also essential.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Guidance for Industry on Drug Master Files: A Refuse to Receive Policy. Retrieved from [FDA Website - specific guidance document URL would be hyperlinked if available and stable]

[2] European Medicines Agency. (n.d.). Active Substance Master Files (ASMF). Retrieved from [EMA Website - specific guidance document URL would be hyperlinked if available and stable]

[3] Evonik Industries AG. (n.d.). RESOMER® Biodegradable Polymers for Controlled Release. Retrieved from [Evonik Website - product page URL would be hyperlinked if available and stable]

[4] Catalent. (n.d.). Parenteral Drug Manufacturing. Retrieved from [Catalent Website - service page URL would be hyperlinked if available and stable]

[5] Lonza. (n.d.). Injectable Drug Products. Retrieved from [Lonza Website - service page URL would be hyperlinked if available and stable]

Suppliers and packagers for RISPERDAL CONSTA